|
|
|
|
LEADER |
02486nam a2200193Ia 4500 |
001 |
10.1136-postgradmedj-2020-139172 |
008 |
220510s2022 CNT 000 0 und d |
020 |
|
|
|a 14690756 (ISSN)
|
245 |
1 |
0 |
|a Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis
|
260 |
|
0 |
|b NLM (Medline)
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1136/postgradmedj-2020-139172
|
520 |
3 |
|
|a PURPOSE: Observations studies have shown that prior use of statins is associated with a reduced risk of adverse clinical outcomes in patients with COVID-19. However, the available data are limited, inconsistent and conflicting. Besides, no randomised controlled trial exists in this regard. Hence, the present meta-analysis was conducted to provide an updated summary and collate the effect of statin use on clinical outcomes in COVID-19 using unadjusted and adjusted risk estimates. METHODS: PubMed, Scopus and Web of Science databases were systematically searched using appropriate keywords till December 18 2020, to identify observational studies reporting clinical outcomes in COVID-19 patients using statins versus those not using statins. Prior and in-hospital use of statins were considered. Study quality was assessed using the Newcastle-Ottawa Scale. Unadjusted and adjusted pooled odds ratio (OR) with 95% CIs were calculated. RESULTS: We included 14 observational studies pooling data retrieved from 19 988 patients with COVID-19. All the studies were of high/moderate quality. Pooled analysis of unadjusted data showed that statin use was not associated with improved clinical outcomes (OR 1.02; 95% CI 0.69 to 1.50, p=0.94, I2=94%, random-effects model). However, on pooling adjusted risk estimates, the use of statin was found to significantly reduce the risk of adverse outcomes (OR 0.51; 95% CI 0.41 to 0.63, p<0.0005, I2=0%, fixed-effects model). CONCLUSIONS: Statin use is associated with improved clinical outcomes in patients with COVID-19. Individuals with multiple comorbidities on statin therapy should be encouraged to continue the drug amid the ongoing pandemic. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
|
650 |
0 |
4 |
|a infectious diseases
|
650 |
0 |
4 |
|a lipid disorders
|
700 |
1 |
|
|a Banerjee, M.
|e author
|
700 |
1 |
|
|a Bhattacharjee, S.
|e author
|
700 |
1 |
|
|a Pal, R.
|e author
|
700 |
1 |
|
|a Yadav, U.
|e author
|
773 |
|
|
|t Postgraduate medical journal
|